Three Peaks Capital Management Has Lowered Its Constellation Brands (STZ) Position; Techne Has 0.98 Sentiment

May 24, 2018 - By olga

Bio-Techne Corporation (NASDAQ:TECH) Logo

Three Peaks Capital Management Llc decreased Constellation Brands Inc (STZ) stake by 7.54% reported in 2017Q4 SEC filing. Three Peaks Capital Management Llc sold 3,682 shares as Constellation Brands Inc (STZ)’s stock declined 2.39%. The Three Peaks Capital Management Llc holds 45,125 shares with $10.31M value, down from 48,807 last quarter. Constellation Brands Inc now has $41.46 billion valuation. The stock increased 0.31% or $0.66 during the last trading session, reaching $216.58. About 1.48 million shares traded or 0.49% up from the average. Constellation Brands, Inc. (NYSE:STZ) has risen 33.47% since May 24, 2017 and is uptrending. It has outperformed by 21.92% the S&P500.

Techne Corp (TECH) investors sentiment decreased to 0.98 in Q4 2017. It’s down -0.23, from 1.21 in 2017Q3. The ratio has dropped, as 113 institutional investors opened new or increased stock positions, while 115 decreased and sold stock positions in Techne Corp. The institutional investors in our database now own: 35.53 million shares, down from 35.91 million shares in 2017Q3. Also, the number of institutional investors holding Techne Corp in top ten stock positions increased from 1 to 2 for an increase of 1. Sold All: 27 Reduced: 88 Increased: 79 New Position: 34.

Investors sentiment increased to 1.24 in 2017 Q4. Its up 0.10, from 1.14 in 2017Q3. It improved, as 43 investors sold STZ shares while 243 reduced holdings. 97 funds opened positions while 257 raised stakes. 140.30 million shares or 2.61% less from 144.05 million shares in 2017Q3 were reported. Hl Financial Serv Lc stated it has 0.23% in Constellation Brands, Inc. (NYSE:STZ). Usca Ria Limited Liability Co stated it has 0.2% of its portfolio in Constellation Brands, Inc. (NYSE:STZ). Cypress Capital Management Ltd Com (Wy) accumulated 5,733 shares. Moreover, Ledyard Bancshares has 0% invested in Constellation Brands, Inc. (NYSE:STZ). Moreover, Sun Life Fincl has 0.01% invested in Constellation Brands, Inc. (NYSE:STZ). Patten Gp holds 0% or 35 shares in its portfolio. Stifel Fincl invested in 0.06% or 89,748 shares. Moreover, Voloridge Invest Mngmt Ltd has 0.42% invested in Constellation Brands, Inc. (NYSE:STZ). Earnest Prtn Limited has 0% invested in Constellation Brands, Inc. (NYSE:STZ). Banced Corp owns 1,720 shares. State Street Corp stated it has 0.13% in Constellation Brands, Inc. (NYSE:STZ). Tompkins Finance stated it has 0.03% of its portfolio in Constellation Brands, Inc. (NYSE:STZ). Freshford Capital Mgmt Limited Liability Corp invested in 11.78% or 279,601 shares. Sandy Spring Financial Bank reported 8,250 shares or 0.17% of all its holdings. Nomura Holdg stated it has 12,983 shares.

Analysts await Constellation Brands, Inc. (NYSE:STZ) to report earnings on July, 5. They expect $2.48 earnings per share, up 5.98% or $0.14 from last year’s $2.34 per share. STZ’s profit will be $474.72M for 21.83 P/E if the $2.48 EPS becomes a reality. After $1.90 actual earnings per share reported by Constellation Brands, Inc. for the previous quarter, Wall Street now forecasts 30.53% EPS growth.

Among 23 analysts covering Constellation Brands (NYSE:STZ), 15 have Buy rating, 0 Sell and 8 Hold. Therefore 65% are positive. Constellation Brands had 83 analyst reports since August 27, 2015 according to SRatingsIntel. Morgan Stanley maintained it with “Buy” rating and $21800 target in Monday, July 10 report. The stock has “Overweight” rating by Barclays Capital on Thursday, December 17. On Monday, July 24 the stock rating was downgraded by Goldman Sachs to “Neutral”. Susquehanna maintained Constellation Brands, Inc. (NYSE:STZ) rating on Monday, June 26. Susquehanna has “Hold” rating and $16200 target. BMO Capital Markets initiated the stock with “Buy” rating in Monday, February 5 report. The firm has “Buy” rating given on Friday, January 8 by Stifel Nicolaus. The stock of Constellation Brands, Inc. (NYSE:STZ) earned “Buy” rating by Cowen & Co on Wednesday, August 2. UBS maintained the shares of STZ in report on Friday, April 7 with “Neutral” rating. The stock of Constellation Brands, Inc. (NYSE:STZ) earned “Buy” rating by Cowen & Co on Monday, October 16. The firm has “Neutral” rating by Citigroup given on Monday, April 11.

More recent Constellation Brands, Inc. (NYSE:STZ) news were published by: Investorplace.com which released: “20 Stocks Hedge Fund Managers Are Buying In Bulk” on May 23, 2018. Also Seekingalpha.com published the news titled: “Tracking Dan Loeb’s Third Point Portfolio – Q1 2018 Update” on May 22, 2018. Investorplace.com‘s news article titled: “3 Common Recommendations That Are Just Plain Bad Investment Advice” with publication date: May 23, 2018 was also an interesting one.

Three Peaks Capital Management Llc increased Summit Matls Inc stake by 132,932 shares to 340,041 valued at $10.69M in 2017Q4. It also upped Pinnacle Foods Inc Del (NYSE:PF) stake by 55,463 shares and now owns 231,461 shares. Equinix Inc (NASDAQ:EQIX) was raised too.

Since January 30, 2018, it had 0 buys, and 4 insider sales for $6.69 million activity. Shares for $441,943 were sold by FROMBERG BARRY A on Tuesday, January 30. $1.47M worth of Constellation Brands, Inc. (NYSE:STZ) was sold by LOCKE JAMES A III on Tuesday, April 17. The insider Klein David Eric sold $4.09M.

Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $845,235 activity.

Analysts await Bio-Techne Corporation (NASDAQ:TECH) to report earnings on August, 14. They expect $1.19 earnings per share, up 16.67% or $0.17 from last year’s $1.02 per share. TECH’s profit will be $44.71 million for 32.07 P/E if the $1.19 EPS becomes a reality. After $1.13 actual earnings per share reported by Bio-Techne Corporation for the previous quarter, Wall Street now forecasts 5.31% EPS growth.

More notable recent Bio-Techne Corporation (NASDAQ:TECH) news were published by: Investingnews.com which released: “5 Top Weekly NASDAQ Tech Stocks: Index Dips Again” on May 13, 2018, also Forbes.com with their article: “New High For Apple But These 5 Other Nasdaq Favorites Failed To Get There” published on May 05, 2018, Investingnews.com published: “Harvest Rebalances Blockchain ETF” on May 23, 2018. More interesting news about Bio-Techne Corporation (NASDAQ:TECH) were released by: Seekingalpha.com and their article: “It’s Time To Add Some ‘Recession Proof’ Dividend Stocks To Your Portfolio” published on May 21, 2018 as well as Seekingalpha.com‘s news article titled: “Bio-Techne (TECH) Q3 2018 Results – Earnings Call Transcript” with publication date: May 02, 2018.

The stock increased 0.33% or $0.5 during the last trading session, reaching $152.63. About 68,884 shares traded. Bio-Techne Corporation (TECH) has risen 45.31% since May 24, 2017 and is uptrending. It has outperformed by 33.76% the S&P500.

Ratings analysis reveals 100% of Bio-Techne’s analysts are positive. Out of 2 Wall Street analysts rating Bio-Techne, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $115.0 while the high is $115.0. The stock’s average target of $115 is -24.65% below today’s ($152.63) share price. TECH was included in 2 notes of analysts from January 18, 2017. The firm has “Buy” rating given on Thursday, February 9 by Citigroup. Deutsche Bank initiated it with “Buy” rating and $115.0 target in Wednesday, January 18 report.

Brown Capital Management Llc holds 3.19% of its portfolio in Bio-Techne Corporation for 2.03 million shares. Stone Run Capital Llc owns 39,925 shares or 2.66% of their US portfolio. Moreover, Summit Creek Advisors Llc has 2.57% invested in the company for 105,782 shares. The Minnesota-based Mairs & Power Inc has invested 2.15% in the stock. Tygh Capital Management Inc., a Oregon-based fund reported 83,128 shares.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $5.74 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 51.56 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Constellation Brands, Inc. (NYSE:STZ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>